HeartBeam Inc. (NASDAQ: BEAT), a medical technology company dedicated to advancing cardiac care, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2026. The call will also provide strategic updates on key growth initiatives, including the limited commercial launch for arrhythmia assessment, development of an extended-wear patch, heart attack detection programs, and artificial intelligence initiatives.
The company, which focuses on transforming the detection and monitoring of critical cardiac conditions, has developed a cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions. This platform technology synthesizes the signals into a 12-lead ECG, enabling portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians can identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology enablement. The upcoming conference call is expected to provide insight into the progress of these cleared indications and the company’s commercial strategy.
The limited commercial launch for arrhythmia assessment marks a significant step toward widespread adoption of HeartBeam’s technology. The extended-wear patch development aims to enhance continuous monitoring capabilities, while heart attack detection programs focus on early identification of life-threatening events. The AI programs are designed to improve diagnostic accuracy and patient outcomes through advanced data analysis.
Investors and stakeholders can access the conference call by dialing in on May 13, 2026, at 4:30 p.m. Eastern time. For more information about HeartBeam and its technology, visit the company’s newsroom at https://nnw.fm/BEAT. Details on cleared indications for use are available at https://www.heartbeam.com/indications.
The announcement underscores HeartBeam’s commitment to redefining cardiac health management by bringing advanced diagnostic capabilities directly to patients. As the company progresses with its commercial launch and development pipeline, the upcoming earnings call will provide a crucial update on its financial health and strategic direction.
